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INTRODUCTION 
Initial R&D efforts were focused on finding new chemical 
entity with desired molecular structure and physical 
properties. The search for molecular structure of an API 
with optimized therapeutic efficacy and proper physical 
properties is quite difficult. Most of the active 
pharmaceutical ingredients exists in solid state, solid does 
not crystallize on its own it crystallizes several forms 
showing unpredictable crystal properties. There are 
number of approaches can be used to modify solids such as 
solvation, hydration, salting and polymorphism. Apart 
from available approaches of API modification 
cocrystallization is an emerging alternative approach 
enhancement of physical properties. 
 In this study the focus is given on 
cocrystallization as major alternative approaches for 
physical property enhancement. The mechanism of 
cocrystallization and various design strategies used along 
with the examples of cocrystals for optimization specific 
physical property. Co crystal screening, characterization 
and regulatory aspects are also covered. 
Cocrystals are known as crystalline complexes of 
two or more neutral molecular constituents, bound together 
in crystal lattice through non covalent interaction. The 
pharmaceutical co crystal are prepared by combination of 
API and coformer i.e. pharmaceutically acceptable 
molecule inside a crystal lattice. As a matter of fact 
cocrystals increase the diversity of API form. 
Cocrystallization is molecular association of similar or 
different molecules, the network of hydrogen bonds results 
in generation of families in the molecular network. 
Designing of cocrystals 
Crystal design involves the construction of solid 
crystals with acceptable physical properties with respect to 
supra molecular structure assemblies. The molecular 
interactions in the crystalline solids are a result of non 
covalent bonds such as hydrogen bonds between functional 
atoms. Due to interaction between compatible molecular 
assemblies changes in physicochemical properties occurs 
such as Solubility, dissolution rates stability and melting 
point. 
 Cocrystals of caffeine were designed using di 
carboxylic acid as coformer the result found was that 
dicarboxylic acids acts as proton donor as a result 
heteromeric interaction that replaces homomeric 
interaction, Heteromeric interactions contains O-H—N and 
C-H—O bonding1. 
 
Figure 1: Molecular interactions of caffeine- Glutaric acid cocrystals containing heteromeric interactions 
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COCRYSTALS IN COMPARISION WITH OTHER   
SOLID MODIFICATION TECHINQUES 
Polymorphs 
 The phenomenon which indicates two or more 
different arrangement of same molecules showing different 
physicochemical properties is termed as polymorphism 
2
.  
It is not possible to predict number of   polymorphs even 
for a simple molecule 3.  Some compounds shows more 
than ten crystal forms4. As known the selection of solid 
modification technique is based on evaluation of solid and 
scope of screening method. In case of cocrystals the 
screening is fairly simple the main part is to identify 
suitable pharmaceutical acceptable coformer. The 
detection of polymorphs is a major challenge for 
investigators it requires high through put screening 
method5. 
Polymorphism is an essential approach for designing 
of cocrystals. Polymorphs can be converting from unstable 
polymorphs to stable polymorph at specific temperature 
and them posses different melting point and solubility 
results in difference in dissolution rate. A few examples of 
polymorphic cocrystals are nicotinamide-carbamazepine 
cocrystals and carbamazepine-saccharine cocrystals6. 
Cocrystals of piroxicam with carboxylic acid were 
prepared in that piroxicam and hydroxybenzoic acid 
cocrystals found to be polymorphs7. 
 
 
Figure2:Classification of API solid form based on molecular structure
8 
Salts 
 Salting is one another approach for enhancement 
physical properties. Salting involves acid –base reaction 
between API and Acidic or basic substance. 
 Salt is used in the place of free acid and base in 
order of improved solubility, stability and crystalline 
property of pharmaceutical compound. Salt is formed by 
transfer of proton from acid to base. As proton is involved 
one can predict the formation by measurement of pKa 
value. Formation of salts depends upon the arrangement of 
hydrogen molecules in crystals. There are several 
marketed APIs which are result of solid modification by 
salt formation. Salts and cocrystals are two opposite 
aspects of multi component system.The difference between 
cocrystals and salts is that drug and coformer are solids at 
ambient temperature and that the intermolecular 
interactions are nonionic in nature 8-10. 
Solvates and Hydrates 
 Solvates imparts toxicity so their use in 
development of API crystal is rare. Most of solvates are 
biologically toxic in nature. Basic difference between 
solvates and cocrystals is their physical form. If substance 
is liquid at room temperature considered as solvates11. 
 Hydrates are one of the better approaches to 
enhance properties moreover it has noted that 33% of 
molecules capable of forming hydrate12, 13. Due to 
temperature and pressure cycling some hydrates converts 
into anhydrous crystalline form and as a result physical 
property changes. 
PROPERTIES ALTERED BY CO 
CRYSTALIZATION 
 The alteration in molecular structure assemblies 
may lead to changes in physical properties.  The expected 
changes in physicochemical properties would occur such 
as solubility, melting point, stability and other mechanical 
properties. There are some examples which demonstrate 
the changes in physicochemical properties. 
Change in Solubility 
 As solubility affects the absorption and 
bioavailability of drug so solubility enhancement is 
essential phenomenon in case of pharmaceutical research. 
Itroconazole is having very low solubility. 
Itroconazolecocrystals were prepared with use of various 
coformers including di carboxylic acids such as tartaric 
acid, maleic acids, succinic acid and fumaric acid. The 
assessment of dissolution rate was carried out in 
comparison with amorphous form. The result found was 
cocrystals of many folds of increase in dissolution rate14. 
Higuchi and Connors studied the solution complexation 
between co crystal components. Co crystal of ionized drug 
co crystal solubility is mainly depending on solution pH. 
The prediction of this can be done by calculation based on 
degree of ionization and dissociation equillibria of 
cocrystals15, 16. 
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Change in Melting point 
 Melting point is an important property while 
studying the alteration of properties of cocrystallization. 
The lowering of melting point is useful process in 
consideration with pharmaceutical aspects. The solid 
having lower melting point in comparison with other solid 
shows lowered susceptibility to degradation.  
Change in Stability 
 The cocrystallization in many cases improves the 
stability of the solid form. As the alteration in molecular 
assemblies changes the mechanical property of solid, the 
stability of polymorphic cocrystals is major concern for 
investigators. The example of polymorphic cocrystals is 
Carbamazepine with saccharin and nicotinamide as 
coformer. These cocrystals are more stable than original 
API17. 
Miscellaneous properties changes 
  The changes in the crystalline structure the 
mechanical aspects also changes such as tensile strength 
and tabletability. For example Paracetamolcocrystals were 
evaluated for tabletability. The evaluation of four 
cocrystals was done in terms of tensile strength, breaking 
force and other elastic properties. These properties are 
beneficial in the designing of dosage form including 
compression phenomenon18. Cocrystallization can also 
alter hygroscopicity of API and avoid undesired molecular 
interaction in the crystal to form solvate or hydrates19.  
Methods used for Cocrystal preparation 
 The most conventional method used for crystal 
formation the use of suitable solution with proper degree 
of super saturation. There are several methods through 
which solution is supersaturated such as evaporation, 
cooling and incorporation of solubility lowering solvent or 
substance.  The most common technique used for 
preparation of cocrystals is the evaporation. 
Cocrystallization through solution evaporation based 
crystal growth technique did not offer optimal result. 
 Some of a few more some established techniques 
that currently used for co crystal formation such as 
mechanical co crystal synthesis and solvothermal co 
crystal synthesis. In mechanochemicalcocrystallization the 
suitable ratios of reactants are grinded to produce phase 
transformation in to crystalline form. Solvothermal method 
involves the dissolution of suitable ratios of reactants in 
solvent undergoing supersaturation20-22. There are several 
factors that involves to both of these processes such 
stability of reactants and condition selected for synthesis. 
a) Solvent Evaporation: 
This is most conventional technique of 
cocrystallization which includes super saturation of 
solution by evaporation, cooling and addition of solubility 
changing solvent or substance. The series of events that are 
follows in solvent evaporation are preparation of two or 
more suspensions by dissolution of stoichiometric amounts 
of materials in a solvent, mixing of suspensions and 
storage under suitable temperatures for co-crystallization. 
In evaporation process the solution of multiple molecules 
in suitable amounts are assumed to undergo hydrogen 
bonding. To have optimal result during evaporation the 
thermodynamic stability of molecules should always be 
considered. The major drawback of evaporation process is 
its failure to comply in large scale preparations. 
The intrinsic dissolution rate was increased of 
Fluoxetine hydrochloride by using multiple coformers like 
succinic acid, fumaric acid and benzoic acid. 
Norfloxacincocrystals were synthesized with 
Isonicotinamide, Malonic acid and maleic acid as 
coformers23. 
 
b) Solid state grinding 
Solid state grinding is alternative synthetic 
method for solution based cocrystallization process. 
Particle size reduction is carried out in mixture which 
increases the covalent reactivity. This method offers 
increase in selectivity and simplicity over solution 
crystallization technique.  
The application of solid state grinding was 
studied using six cocrystals of sulfadimidine with 
anthranillic acid and salicylic acid, the co crystal of 
sulfadimidine –salicylic acid while grinding with 
anthranillic acid. The replacement of Salicylic acid with 
anthranillic acid occurs as a result of common pattern of 
hydrogen bonding of both of cocrystals24. 
The hydration of caffeine is reported but the study 
of preparation by solid grinding in a ball mill is also 
proved25. The hydrogen bonding preferences was 
demonstrated in number of instances for modification in 
solid grinding technique26. The solid grinding generated 
cocrystals which were not possible by solutionevaporation. 
This method was used for generation of cocrystal phase 
with various coloristic properties27. The solid grinding 
approach is having drawback of polymorphic transition 
during the process which results in dangerous side effect 
that may includes permanent withdrawal from market. 
 
c) Solvent drop grinding 
Solvent drop grinding is emerging step in 
advancement of polymorphic selectivity in various models 
of cocrystals. Solvent drop grinding includes grinding of 
two materials together like solid state grinding with 
incorporation of small quantity of solvent. The solvent 
added act as   catalyst.  It is anticipated that this approach 
will open new opportunities in both the synthesis and 
characterization of co-crystals, regardless of the inabilities 
to characterize materials synthesized using this method by 
single-crystal X-ray diffraction28. 
For determining efficacy of methods for synthesis 
the cocrystals the cyclohexane tricarboxyllic acid 
derivatives are used. Initially their synthesis is carried out 
by solution crystal growth method. Some crystals were 
readily prepared with solid grinding method but some did 
not successfully preceded further. For them solvent drop 
grinding technique found to be efficient29. 
The inability of Solid grinding process for 
selective polymorphic synthesis of caffeine and Glutaric 
acid co crystal was successfully fulfilled by solvent drop 
grinding. The example of two polymorphs is having 
identical hydrogen bonding assemblies but different 
stacking arrangement. Solid grinding technique only 
nonselectively shows Type 1 polymorphs synthesis. While 
in case of solvent drop grinding with polar solvent shows 
synthesis of Type1 in absence of Type II and Pure 
preparation of Type II similarly. The applications of 
solvent drop technique in inter converting polymorphic 
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organic substances in case of carboxylic acids like succinic 
acid and anthranillic acid30. Solvent drop grinding is useful 
in synthesis of crystalline salt with pharmaceutical 
substances. Indomethacin cocrystals with saccharine were 
prepared by solvent drop grinding, the optimal result 
obtained with increased dissolution rate and physical 
stability
31
. 
 
d) Slurry Crystallization 
Slurry crystallization is simple process which 
includes the addition of crystallization solvent in the 
components i.e. API along with its acceptable former. The 
selection of this process is mainly depends upon the 
physical stability of the crystallization solution to co 
crystals and its solid former. The study on synthesis of 
cocrystals through Slurry crystallization was commenced 
in   sixteen co crystal system with optimum result32 
While preparation of cocrystals for Trimethoprim 
and sulfamethoxazole through slurry technique simple 
distilled water is used as solvent. Cocrystals of aspirin 
designed with 4, 4-Dipyridil as a coformer by using slurry 
crystallization method. However the yield obtained was 
not sufficient as compared with solvent drop grinding 
method33. The major disadvantage of this method is that it 
requires large amount of solvent. 
 
e) Hot melt extrusion 
Extrusion is useful method for synthesis of 
cocrystals, it involves highly efficient mixing and 
improved surface contacts, Co crystals are prepared 
without use of solvent. The selection of this method is 
primarily depends on thermodynamic stability of 
compound. This method was studied with the use of four 
models for cocrystal formation34. 
Solvent drop extrusion technique used to optimize 
and make the process more flexible. Solvent drop 
extrusion technique gives an advantage to carry out 
process at lower temperature. Hot melt extrusion method 
was used in synthesis of Carbamazepine-
nicotinamidecocrystals with polymer as former35. 
Continuous cocrystallization, API and coformer poured in 
the twin extruder. As a result of continuous addition of 
mixture the barrel temperature also increases. 
f) Sonocrystallization Method 
The development of sonochemical method for 
preparation of organic cocrystals of very finite size has 
been done. This method was primarily developed for 
preparation of nanocrystals. Caffeine- maleic acid 
cocrystal preparation commenced with use of ultrasound 
method36. 
 The comparative study of method of preparation 
of caffeine and theophylline as API and L-tartaric acid as 
coformer by Solvent drop grinding method and 
sonochemical method has been commenced37. The results 
of methods were consistent hence Sonocrystallization 
proves to be a significant approach. 
MOLECULAR MECHANISM OF CO CRYSTAL 
FORMATION  
 The co crystal formation studies mainly aimed at 
understanding the design of cocrystal. In early study 
approach based on hydrogen bond rules includes certain 
assumption that all good proton donors are used in 
hydrogen bonding and every good donor finds a suitable 
acceptor in crystalline structure38 
The numerous studies based on method of 
preparation such as during the co grinding and storage the 
generation of amorphous phase led to co crystal 
formation39. There are several examples of co crystal 
formation by moisture uptake such as Caffeine, 
carbamazepine-nicotinamide, carboxylic acid.  The 
mechanochemicalcocrystallization mechanism involves the 
competitive behavior of intermolecular halogen bonds. The 
further formation of finite molecular arrangement of 
competing strong halogen bonds which progresses to 
polymerization of infinite chain cross linking through 
strong intermolecular halogen bonds. 
COCRYSTAL SCREENING 
 The purpose behind screening is to discover co 
crystal with enhanced physical properties. The 
cocrystallization involves interaction two molecules with 
compatible structural assemblies interact. The co crystal 
formation is mainly depend upon acceptability of 
coformer,  ratio of  solid and coformer and type of method 
used for synthesis. The cocrystals can be synthesized by 
several methods such as solvent evaporation, solid 
grinding, solvent- drop grinding technique and hot melt 
crystallization. The initial assessment of method of 
synthesis is done by yield of cocrystals obtained. In all 
these processes the most common and conventional 
method is solvent evaporation. The disadvantage of this 
method is inability to scale up. Solvent drop grinding was 
found to be efficient and effective in discovery of newer 
cocrystals but in the preparation of co crystal hydrates it 
was found to be less sensitive to reactant. The other 
methods such as slurry crystallization were found to be 
effective in case of stonolone and metastonolon with 11 
acids as coformer the yield was good.  
  There are few methods which are used for 
screening of cocrystals such includes near infrared 
spectroscopy which was evaluated for co crystal screening 
in comparison with Raman spectroscopy. In this study 
Indomethacin was used as parent drug with L-aspartic acid 
and saccharin as coformer. The molar ratio of 1:1 with 
each coformer was selected. For the preparation cocrystals 
two methods are used, in case of saccharin the solvent drop 
technique is used. While for L-aspartic acid the method 
solvent evaporation was used. Raman spectroscopy 
showed straight peaks and shows satisfactory data but near 
infrared does not showed proper results. NIR shows good 
result in combination with multivariate modeling by 
principle component analysis40. 
The development of thermal method for rapid co 
crystal screening was done. The compound sparing most 
efficient and highly automated differential scanning 
colorimetry method developed41.  
Co crystal screening through hot melt microscopy 
was studied. In this method nicotinamidecoformer with 
seven active pharmaceutical ingredients were used. The 
synthon stability of each combination was checked. This 
method allowed identification of thermodynamic 
landscape within the binary phase and make the screening 
more efficient42. 
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Screening of cocrystals with similar structure was 
carried out. Piracetam and Levitiracetam are structurally 
similar. The synthesis of Piracetamcocrystals with 10 
different acids had been studied. For the experimental 
work these ten acids were used to form cocrystals of 
Levitiracetam. The profound result   obtained with 40% 
success rate 
43
. 
The co crystal hydrates were screened with 
solvent drop grinding method. The study on all the 
preparation method was carried out by considering 
variables along with combination of these techniques and 
its effect on co crystal formation44. Recently for co crystal 
of caffeine and adipic acid newer screening methods are 
used. The capability of co crystal formation for antiviral 
drugs like lamivudine and zidovudine were analyzed45. 
The application of newer synthetic approaches for 
designing of cocrystals was studied. Cocrystals of 
itroconazole-succinic acid characterization are done by 
single crystal x-ray. The comparative study on two 
structurally identical solids was carried out. Trimethoprim 
and pyrimethamine with carboxylic acid salts used as 
coformer. The cocrystals were prepared by various 
methods and evaluated by different techniques. Among all 
these methods the solid grinding and solvent-drop grinding 
was found to be efficient screening tool46. 
The cocrystals of caffeine and oxalic acid were 
evaluated for the stability in various different conditions. 
The different stoichiometric ratios of compound with 
submeric acid and nicotinamide as coformer were studied 
for stepwise assessment of co crystal formation. The 
Indomethacin-saccharin cocrystals were used as model for 
evaluation of supercritical solvent technique for 
screening47.  The cocrystals of Norfloxacinsaccharinate-
saccharin dehydrate cocrystals were prepared and 
evaluated for enhanced physical properties48. The study of 
polymorphic cocrystals of phloroglucinol and phenalzine 
were carried out. In that different stoichiometric ratios 
were taken and role of coformers as hydrogen bond 
additives for stability in crystallization process49.   
COCRYSTAL CHARECTERIZATION 
 The co crystal characterization is involves 
structural assessment and properties evaluation. There are 
several analytical techniques which are used for 
characterization of crystal structures and properties 
evaluation.  
Table 2: shows various methods involving determination of structure & properties for several cocrystals
50-52, 45, 47, 53 
The cocrystal were synthesized with solvent evaporation 
method and solid grinding then characterized by DSC, IR, 
PXRD and single crystal X-ray diffraction54. Cocrystals 
are synthesized by grinding and slurring was characterized 
by single crystal x-ray diffraction. Solid state NMR has 
also generated recent interest in order to characterize 
cocrystals. The advantage of using solid state NMR 
spectroscopy is that it has the ability to differentiate chiral 
and racemic cocrystals of similar structure. The 
comparison of molecular salt and cocrystals solubility 
were carried out by mathematical model55. The formation 
of cocrystals can be predictable with the assessment of 
thermodynamic stability. 
REGULATORY ASPECTS OF COCRYSTALS  
 Solid form can possess unwanted physical 
properties but with the proper efforts creative and useful 
thing could occur. For anything to be eligible for 
patentability criteria it should have three important things 
utility, novelty and non-obviousness. While considering 
patentability criteria for cocrystals always compared with 
pharmaceutical salts. The novelty of cocrystals for 
modification of API is far greater than salts56. The utility 
considered with therapeutic aspects can be suggested with 
cocrystallization. The physical properties such as solubility 
and dissolution rate enhancement will result in increased 
therapeutic utility.  
 The non-obviousness is inability to predict the 
crystal structure. The visual prediction of crystalline 
structure is not possible. The more advance techniques 
such as computational predicament for plausible structure 
are being used by researcher57. 
 The main regulatory issue regarding cocrystals is 
that it is yet to be approved by generic regulatory 
department. The cocrystals applications are submitted in 
ANDA form. Pharmaceutical cocrystals are having 
commercial advantage with respect to market. In 
comparison with other solid modification approaches 
cocrystallization is having scientific and regulatory 
advantage. 
CONCLUSION AND FUTURE SCOPE 
 Cocrystallization is significant type of process in 
the development and optimization of new therapeutic 
entity as well as existing one. The relation of 
cocrystallization process in the API formulation involves 
optimized physical properties such as solubility, stability, 
melting point and other properties. The major venture 
includes characterization, Identification and development 
of new and existing drug. Among the process of 
manufacturing of cocrystals solid grinding and solvent 
drop grinding tends to demonstrates higher selectivity than 
other solvent based process.  Comparing with other solid 
modification techniques used in pharmaceutical industry, 
Cocrystallization appears to be alternative tool in drug 
discovery.  
 Cocrystallization is new process for 
pharmaceutical industry; more research needs to be done 
to scale up this process for application in manufacturing 
Sr. no Determinant    Characterization method Examples 
1 Structure Single crystal x-ray crystallography Tiotropiumfumarate 
Powder x-ray diffraction Gossypol-carboxyllic acid 
Raman spectroscopy Gabapentin-oxallic acid 
Near infra red spectroscopy L-aspatic acid-saccharin 
2 Properties Differential scanning colorimetry Indomethacin-saccharin 
Thermo gravimetric analysis Theophylline-nicotinamide 
Melting point apparatus Sulfamerazine-salicyllic acid 
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and development of new dosage form. The major concern 
for investigators is screening of cocrystals which includes 
high throughput assessment of molecular structure of API 
and suitable coformer. There is need of development of 
proper screening methodology in order to ease 
cocrystallization and its regulatory criteria.  
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